WAVE Life Sciences Ltd (NAS:WVE)
$ 5.74 0.22 (3.99%) Market Cap: 716.00 Mil Enterprise Value: 590.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 63/100

WAVE Life Sciences Ltd at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 11:00PM GMT
Release Date Price: $5.3 (-0.56%)
Eric Joseph JPMorgan;Analyst

Okay. Good afternoon. I'm Eric Joseph, Senior Biotech Analyst with JPMorgan. And our next presenting company is WAVE Life Sciences. Presenting on behalf of the company is CEO Paul Bolno. There's a Q&A session after the presentation. We'll bring mics around for folks who have questions. And for folks joining via webcast, you can submit questions via the portal. So with that, Paul, thanks for joining us.

Paul Bolno
WAVE Life Sciences Ltd - Independent Director

Thank you, Eric. And it's great to have an opportunity to present here today and provide an update on the tremendous progress that the team has been making at WAVE. Before we begin, we'll obviously be making some forward-looking statements today, so please refer to our SEC filings.

I think before we start, it's really important, as a reminder to those who are also new to the story of WAVE, to really remind people who we are and what we're doing. WAVE is a clinical-stage RNA medicines company, bringing over a decade of oligonucleotide chemistries innovations

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot